Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor
Nigro, L.; Romano, F.; Tosto, S.; Zagami, A.; Bruno, S.; Nunnari, A.
Italian Journal of Gastroenterology and Hepatology 31(1): 85-86
1999
ISSN/ISBN: 1125-8055 PMID: 10091111 Document Number: 502813
Document emailed within 1 workday
Related Documents
Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455Lobello, S.; Lorenzoni, U.; Vian, A.; Floreani, A.; Brunetto, M.R.; Chiaramonte, M. 1998: Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring Journal of Viral Hepatitis 5(1): 61-66
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Ozeki, I.; Karino, Y.; Toyota, J. 2011: Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 267-274
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
González, N.; Rodríguez, N.; Tripari, J.; Cantisani, M.; Morán, N.; Soto, S.; Feliciano, C.; Ramos, P.; Yamamura, Y. 1998: RT-PCR comparative study of viral load levels in the HIV positive population in Puerto Rico before and after protease inhibitor regimen implanted Boletin de la Asociacion Medica de Puerto Rico 90(1-3): 16-20
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Lin, W.H.; Feng, H.-P.; Shadle, C.R.; O'Reilly, T.; Wagner, J.A.; Butterton, J.R. 2014: Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone European Journal of Clinical Pharmacology 70(9): 1107-1113
Sabo, J.P.; Lang, B.; Elgadi, M.; Huang, F. 2015: Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers Antimicrobial Agents and ChemoTherapy 59(1): 514-519
Buch, H.J. 1970: Treatment of arthrosis with protease-inhibitor Contrykal Das Deutsche Gesundheitswesen 25(20): 947-950
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Armignacco, O.; Andreoni, M.; Sagnelli, E.; Puoti, M.; Bruno, R.; Gaeta, G.Battista.; Perno, C.F.; Santantonio, T.A.; Bonfanti, P.; Bonora, S.; Borderi, M.; Castagna, A.; d'Arminio Monforte, A.; De Luca, A.; Grossi, P.; Guaraldi, G.; Maggiolo, F.; Mussini, C.; Sagnelli, C.; Tavio, M.; Torti, C.; Uberti-Foppa, C.; Andreoni, M.; Angarano, G.; Antinori, A.; Armignacco, O.; Carosi, G.; Chirianni, A.; Di Perri, G.; Galli, M.; Lazzarin, A.; Rizzardini, G.; Sagnelli, E.; Taliani, G. 2014: Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease new microbiologica 37(4): 423-438
Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56
2000: Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor MMW Fortschritte der Medizin 142(3 Suppl): 8-9
Novelli, G.P.; Innocenti, P.; Livi, P. 1993: Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study Minerva Anestesiologica 59(5): 247-253
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Luber, A.D. 2005: Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes Aids Reader 15(12): 692
Gurgo, A.M.; Massino Ferri, F.; Iulianella, R.; Luciani, C.; Lucifero, A.; Staropoli, P.; Rocchi, M. 2001: Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 2(11): 1236-1239
Dragosics, B.; Pesendorfer, F.; Wewalka, F. 1975: Anti-HBsAg-positive acute hepatitis with a severe disease course Verhandlungen der Deutschen Gesellschaft für Innere Medizin 81: 1353-1356
Xu, J.-h.; Yu, Y.-y.; Si, C.-w.; Chen, X.-y.; Han, Z.-h.; Chen, Y.; Li, X.-y. 2009: A clinical study of viral dynamic change in patients with hepatitis B e antigen positive chronic hepatitis B by lamivudine treatment Zhonghua Yi Xue Za Zhi 89(41): 2902-2905